RxDoctor Payments Data

George Dirani, MD

Cardiovascular Disease · Farmington Hills, MINPI 1619310885

Payments from drug & device makers

$69,619in general payments, 2019–2025

Across 622 payments — averaging $111.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$47K
  • Shockwave Medical, Inc$7K
  • Abbott$2K
  • Stryker$1K
  • Boston Scientific$1K
  • Kestra Medical Technology Services, Inc.$1K
  • plus $9K from 44 others

What the payments were for

  • Consulting fees$5,5658%
  • Speaking & faculty fees$37,50054%
  • Travel & lodging$5,0087%
  • Food & beverage$21,44031%
  • Education$1060%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$69,619 in reported general payments places this provider in the 85th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$615,497
Medicare patients
1,367
Services billed
3,755

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban235$264,008
XareltoRivaroxaban105$92,127
JardianceEmpagliflozin47$54,582
EntrestoSacubitril/Valsartan40$42,920
BrilintaTicagrelor53$35,709
FarxigaDapagliflozin Propanediol32$28,914
MounjaroTirzepatide18$24,581
Repatha SureclickEvolocumab33$20,876
Metoprolol Succinate397$6,385
ClopidogrelClopidogrel Bisulfate231$4,121
Ranolazine ErRanolazine44$3,928
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide85$3,417
Amiodarone Hcl75$2,155
Atorvastatin Calcium147$2,091
Bumetanide62$1,907

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$37$264,008235 claims
Johnson & JohnsonXarelto$767$92,127105 claims
AstraZenecaBrilinta, Farxiga$693$64,62385 claims
Boehringer IngelheimJardiance$826$54,58247 claims
NovartisEntresto$794$42,92040 claims
Lilly USA, LLCMounjaro$151$24,58118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Farmington Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →